Skip to main content
SpringerLink
Log in

Do You Know the Details of Your PAX8 Antibody? Monoclonal PAX8 (MRQ-50) Is Not Expressed in a Series of 45 Medullary Thyroid Carcinomas

  • Published:
Endocrine Pathology Aims and scope Submit manuscript

Abstract

Medullary thyroid carcinomas display cytologic and architectural features that can simulate various primary and metastatic neoplasms. PAX8 immunoexpression in neuroendocrine neoplasms yielded antibody-dependent findings. Since the data regarding the expression profile of monoclonal PAX8 (MRQ-50) antibody is limited in large series of medullary thyroid carcinomas, this study investigated the expression profile of PAX8 (MRQ-50) in a series of 45 medullary thyroid carcinomas. PAX8 (MRQ-50) expression was noted in the thyroid follicular epithelial cells surrounding the tumor and was negative in all medullary thyroid carcinomas. In addition, twenty medullary thyroid carcinomas showed scattered entrapped thyroid follicular epithelial cells at the periphery of the tumor. Entrapped follicular epithelial cells were positive for PAX8 and thyroglobulin, and were negative for monoclonal CEA and calcitonin. A panel approach combining monoclonal antibodies to transcription factors, hormones and cell-specific peptides often assist diagnosticians in the workup of the cellular origin of a neuroendocrine neoplasm. Since PAX8 immunostaining is dependent on the antibody characteristics in neuroendocrine neoplasms, pathologists should be aware of the details of the PAX8 antibody used in a particular case.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Duan K, Mete O. Algorithmic approach to neuroendocrine tumors in targeted biopsies: Practical applications of immunohistochemical markers. Cancer Cytopathol. 2016;124(12):871–884.

    Article  Google Scholar 

  2. Sangoi AR, Ohgami RS, Pai RK, Beck AH, McKenney JK, Pai RK. PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. Mod Pathol. 2011;24(3):412–424.

    Article  CAS  Google Scholar 

  3. Ordóñez NG. Value of PAX 8 immunostaining in tumor diagnosis: a review and update. Adv Anat Pathol. 2012;19(3):140–151.

    Article  Google Scholar 

  4. Liau JY, Tsai JH, Jeng YM, Kuo KT, Huang HY, Liang CW, Yang CY The Diagnostic Utility of PAX8 for Neuroendocrine Tumors: An Immunohistochemical Reappraisal. Appl Immunohistochem Mol Morphol 2016;24:57–63.

    Article  CAS  Google Scholar 

  5. Nonaka D, Tang Y, Chiriboga L, Rivera M, Ghossein R. Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms. Mod Pathol 2008;21:192–200.

    Article  CAS  Google Scholar 

  6. Tacha D, Zhou D, Cheng L. Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. Appl Immunohistochem Mol Morphol 2011;19:293–299.

    Article  CAS  Google Scholar 

  7. Erickson LA, Mete O. Immunohistochemistry in Diagnostic Parathyroid Pathology. Endocr Pathol. 2018;29(2):113–129.

    Article  CAS  Google Scholar 

  8. Ozcan A, Shen SS, Hamilton C, Anjana K, Coffey D, Krishnan B, Truong LD. PAX8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study. Mod Pathol. 2011;24(6):751–764.

    Article  CAS  Google Scholar 

  9. Trueba SS, Auge J, Mattei G, Etchevers H, Martinovic J, Czernichow P et al. PAX8, TITF1, and FOXE1 gene expression patterns during human development: new insights into human thyroid development and thyroid dysgenesis-associated malformations. J Clin Endocrinol Metab 2005;90:455–462.

    Article  CAS  Google Scholar 

  10. Baloch Z, Mete O, Asa SL. Immunohistochemical Biomarkers in Thyroid Pathology. Endocr Pathol. 2018;29(2):91–112.

    Article  CAS  Google Scholar 

  11. Christophe D. The control of thyroid-specific gene expression: what exactly have we learned as yet? Mol Cell Endocrinol 2004;223:1–4.

    Article  CAS  Google Scholar 

  12. Mansouri A, Chowdhury K, Gruss P. Follicular cells of the thyroid gland require Pax8 gene function. Nat Genet 1998;19:87–90.

    Article  CAS  Google Scholar 

  13. Pasca di Magliano M, Di Lauro R, Zannini M. Pax8 has a key role in thyroid cell differentiation. Proc Natl Acad Sci U S A 2000;97:13144–13149.

    Article  CAS  Google Scholar 

  14. Mahia PE, Lapi P, Krude H, Pirro MT, Missero C, Chiovato L et al. PAX8 mutations associated with congenital hypothyroidism caused by thyroid dysgenesis. Nat Genet 1998;19:83–86.

    Article  Google Scholar 

  15. Bishop JA, Sharma R, Westra WH. PAX8 immunostaining of anaplastic thyroid carcinoma: a reliable means of discerning thyroid origin for undifferentiated tumors of the head and neck. Hum Pathol 2011;42:1873–1877.

    Article  CAS  Google Scholar 

  16. Laury AR, Perets R, Piao H, Krane JF, Barletta JA, French C, Chirieac LR, Lis R, Loda M, Hornick JL, Drapkin R, Hirsch MS A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol 2011;35:816–826.

    Article  Google Scholar 

  17. Zhang P, Zuo H, Nakamura Y, Nakamura M, Wakasa T, Kakudo K. Immunohistochemical analysis of thyroid-specific transcription factors in thyroid tumors. Pathol Int 2006;56:240–245.

    Article  CAS  Google Scholar 

  18. Puglisi F, Cesselli D, Damante G, Pellizzari L, Beltrami CA, Di Loreto C. Expression of Pax-8, p53 and bcl-2 in human benign and malignant thyroid diseases. Anticancer Res 2000;20:311–316.

    CAS  PubMed  Google Scholar 

  19. Dörfler P, Busslinger M. C-terminal activating and inhibitory domains determine the transactivation potential of BSAP (Pax-5), Pax-2 and Pax-8. EMBO J. 1996;15(8):1971–1982.

    Article  Google Scholar 

  20. Peters H, Neubüser A, Kratochwil K, Balling R. Pax9-deficient mice lack pharyngeal pouch derivatives and teeth and exhibit craniofacial and limb abnormalities. Genes Dev. 1998;12(17):2735–2747.

    Article  CAS  Google Scholar 

  21. Kameda Y. Cellular and molecular events on the development of mammalian thyroid C cells. Dev Dyn. 2016;245(3):323–341.

    Article  CAS  Google Scholar 

  22. Johansson E, Andersson L, Örnros J, Carlsson T, Ingeson-Carlsson C, Liang S, Dahlberg J, Jansson S, Parrillo L, Zoppoli P, Barila GO, Altschuler DL, Padula D, Lickert H, Fagman H, Nilsson M. Revising the embryonic origin of thyroid C cells in mice and humans. Development. 2015;142(20):3519–3528.

    Article  CAS  Google Scholar 

  23. Singh K, Hanley LC, Sung CJ, Quddus MR. Comparison of PAX8 Expression in Breast Carcinoma Using MRQ50 and BC12 Monoclonal Antibodies. Appl Immunohistochem Mol Morphol 2019. doi: https://doi.org/10.1097/PAI.0000000000000796.

  24. Asa SL, Mete O. Cytology and Pathology of Medullary Thyroid Carcinoma: Pitfalls and Challenges. In Douglas Evans and Tracy S. Wang (eds). Medullary Thyroid Cancer, Springer, Berlin 2016; pp: 33–46.

    Chapter  Google Scholar 

  25. DeLellis RA, Al Ghuzlan A, Abores Saavedra J, Baloch ZW, Basolo F, Elisei R, Kaserer K, LiVolsi V, Matias-Guiu X, Mete O, Moley JF, Nikiforov YE, Nose V, Pinto AE. Medullary Thyroid Carcinomas. In Lloyd RV, Osamura RY, Kloppel G, Rosai J. (eds). WHO Classification of Tumours of Endocrine Organs. 4th edition. IARC: Lyon 2017; pp: 108–113.

    Google Scholar 

  26. Hyrcza MD, Winer D, Mete O. Images in endocrine pathology: papillary variant of medullary thyroid carcinoma with cystic change. Endocr Pathol. 2015;26(1):87–89.

    Article  Google Scholar 

  27. Suster S. Thyroid tumors with a follicular growth pattern: problems in differential diagnosis. Arch Pathol Lab Med. 2006;130(7):984–988.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Recep Tayyip Erdogan University, Rize, Turkey

    Hasan Gucer

  2. Department of Pathology, Ondokuz Mayis University, Samsun, Turkey

    Sultan Caliskan & Mehmet Kefeli

  3. Department of Pathology, University Health Network, Toronto, ON, Canada

    Ozgur Mete

  4. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada

    Ozgur Mete

Authors
  1. Hasan Gucer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sultan Caliskan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mehmet Kefeli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ozgur Mete
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

HG: concept and design of the study, literature review, data analysis, material contribution and manuscript writing. SC, MK: material contribution and data analysis. OM: concept and design of the study, literature review, manuscript writing, and confirmation of the final version of the submission.

Corresponding authors

Correspondence to Hasan Gucer or Ozgur Mete.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical Statement

Institutional REB approvals were obtained.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gucer, H., Caliskan, S., Kefeli, M. et al. Do You Know the Details of Your PAX8 Antibody? Monoclonal PAX8 (MRQ-50) Is Not Expressed in a Series of 45 Medullary Thyroid Carcinomas. Endocr Pathol 31, 33–38 (2020). https://doi.org/10.1007/s12022-019-09603-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12022-019-09603-3

Keywords

Search

Navigation